Upstream Bio (UPB) shares saw an increase in after-hours trading on Friday following the company's presentation of ...

Dupixent demonstrated superior efficacy in reducing nasal polyp size and improving smell in CRSwNP, as well as enhancing lung function and disease control in asthma, with benefits observed as ...

In the EVEREST trial, 360 adults with severe, uncontrolled CRSwNP and coexisting asthma were randomized to receive Dupixent 300 mg (n=181) every two weeks or a weight- and immunoglobulin E (IgE ...

Type 2 CRSwNP is linked to worse health-related quality of life, with higher rates of smell loss and rhinorrhea emerging as ...

Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

Currently, verekitug is being evaluated in Phase 2 clinical trials for severe asthma and CRSwNP, with plans to initiate trials in COPD, showcasing its potential to address unmet medical needs in ...

In patients with chronic rhinosinusitis with nasal polyps, factors including baseline antibiotic use and asthma impacted the ...

The approval in adolescent patients with CRSwNP was also supported by pharmacokinetic data from adult and pediatric patients aged 12 years and older with moderate to severe asthma and adult ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed ...